To OTC Journal Members:
 

ACTC: Biggest  Percentage One Day Gain Ever in OTC Journal

Wow- what an explosion. Any one out there following this stock? Took off like the Space Shuttle leaving Cape Kennedy. More follow through in the early going today. Yesterday was unbelievable- it might be the biggest one day percentage gain I have ever witnessed over eight years of publishing the OTC Journal. The stock appreciated 357.5% in one day. Absolutely breathtaking.

In case you haven't seen the news, here's the scoop. Nature Magazine published a very in depth article on the strides ACTC has made with its Stem Cell technology.

The article was entitled "Human Embryonic Stem Cells Lines Derived From Single Blastomeres". If you are interested in this company and their technology, you should read the article. I have read it twice, and still don't understand a lot of it. However, even the layman can understand the significance of the science. Of course, I have a PDF version of the article for your convenience. Simply Click Here, and you the article will blow open on your computer.

Here's where I self promote a little. Bear with me. OTC Journal followers know I am a big believer in the future of Stem Cell technology. I also believe Stem Cell stocks will trade very well in the future. Between the energy obsession of the past 18 months, the market blow off in June and July, and the low volume summer months, the stem cell sector has been all but forgotten.

I try to uncover microcap situations that you wouldn't hear about on your own, give you the facts, share my views as to what might happen, and let you decide if you like the idea. In the case of Advanced Cell, my first publication was March 27, 2006. By clicking on the date you can go back and read the original presentation.

The article, which appears in the current edition of Nature Magazine, contains no new information that you didn't have in my original presentation. It talks at length about ACTC's ability to derive a fetal stem cell line from a Blastomere without harming the potential for life. The article simply chronicles the scientific process. There was no major breakthrough you didn't already know about. ACTC simply received validation from the scientific community, and it translated into a massive move in the stock.

Furthermore, if you read the quote at the top of the article, you should recognize I called for the possibility of high profile media coverage on this company. After, they've been in the Wall Street Journal twice already.

Hence, the value of the OTC Journal. We found this one long before it was on anyone's radar screen and chronicled the possibilities for the technology.

Take a look at this chart. You won't find anything like this chart in any other microcap publication. It gives you more detailed information than anyone else will provide.

Here's what strikes me about the chart. Note the stock surges to $3 last October when the Wall Street Journal publishes on the company. Nice move, big spike.

Then there's yesterday's massive spike on the chart associated with the Nature article. As it relates to the starting price, the spike is considerably longer. However, the most striking feature is the enormous amount of  volume level at the bottom of the chart. It simply dwarfs any other day's volume in the stock's trading history.

You want to know where I think the stock is going from here? Hard to say. There might be a couple more days of spiky surges. The recognition from the article is just beginning. The company is holding a conference call on Friday at 12:00 Pacific to discuss the developments. You can dial in at (800) 230-1074, when prompted tell the operator you would like to connect to the 'Advanced Cell Technology conference call.'

OTC Journal followers know I am a believer in accumulating microcap stocks when they are quiet and no one wants them. If you believe in the company, you simply wait for the epiphanal events to be a seller or an observer. Not a buyer.

If you own ACTC and hung in there during the multi month decline, congratulations. Sometimes the old fashioned buy and hold mentality works best. If you don't own it and you want to, I would not jumping into a full position at these levels. Don't forget about their toxic financing. It promises to create excess supplies every month for the foreseeable future. Go 1/3 now, and look to add the other 2/3s during quieter times.

One thing may change about this stock permanently- the amazing amount of volume may put this company on a lot more radar screens over the coming months and years. It might hold up much better as more investors learn about it and want to own a piece.

I'll probably post a BLOG on Monday morning with a review of the trading activity. It will give you a current opportunity to ask any questions or share any comments.

This is one that needs to go in the "own and forget about it" end of your portfolio. You can still accumulate it right. The company has many years of scientific achievement ahead of it.
 

Subscribe

Information is power and timely information is profitable. Become informed and profit from OTC Journal Profiles and Trading Alerts by becoming a Preferred Member today. There is no cost associated with your email subscription. Add your email address below and make sure to check your email inbox and confirm your opt-in request to start receiving the OTC Journal Email Newsletter on a regular basis.

To ensure newsletter delivery, you can add any additional email addresses you may have to the OTC Journal Member List. Receiving the OTC Journal Newsletter in multiple locations is the best way of making sure you don't miss the next investing or trading opportunity! For web based email addresses, the OTC Journal recommends @yahoo.com or @aol.com for timely and reliable email newsletter delivery.

Note: Your email address will be kept strictly confidential, and will not be shared with any other entity for any purpose at any time. If you no longer wish to receive the OTC Journal, simply follow the instructions located at the bottom of every OTC Journal Newsletter Edition.

Go Here to view our compensation on every company we have ever covered, or visit the following web address:  http://www.otcjournal.com/disclaimer.html for our full profiles and http://www.otcjournal.com/trading-alerts/disclaimer.html for Trading Alerts.MarketByte LLC has been paid a fee of $30,000 and 250,000 warrants, exercisable at $2.54, by Advanced Cell Technology for coverage of the company.

All statements and expressions are the sole opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the newsletter is neither an offer nor solicitation to buy or sell any securities  mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.

From time to time MarketByte LLC sells shares in the open market it receives as compensation for coverage of client companies. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, the editors do not view the sale of the shares as contradictory to any advice delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies.

The editor, members of the editor's family, and/or entities with which they are affiliated aside from MarketBtye LLC itself, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed in the newsletter. Some of the companies featured in the OTC Journal pay a cash ESP fee to an affiliated technology company ranging from $2,000 to $5,000 per month for internet related technology services.

The Trustee of the MarketByte LLC Defined Benefit and Trust (“the MarketByte Pension Plan”) has invested approximately $140,0000 in Dutchess Private Equities II LP (“the Dutchess Limited Partnership”), a limited partnership in which the MarketByte Pension Plan is a limited partner. The Trustee of the MarketByte LLC Defined Benefit and Trust (“the MarketByte Pension Plan”) has invested approximately $190,0000 in the Longview Fund (“the Longview Limited Partnership”), both limited partnerships in which the MarketByte Pension Plan is a limited partner. No one associated with the MarketByte Pension Plan has any knowledge, information, or control as to any past, present, or future investment activities of the Dutchess Limited Partnership or the Longview Fund.  The Dutchess Limited Partnership is one of two hedge funds managed by Dutchess Advisors.  Dutchess Advisors and Longview periodically refers companies to MarketByte LLC for possible coverage by one of the MarketByte LLC publications, which publications include The OTCJournal.com Newsletter.  Dutchess Advisors or Longview may or may not own shares in the companies that it so refers to MarketByte. MarketByte has no information (outside of information readily accessible to the general public such as SEC filings) as to whether Dutchess Advisors or Longview owns any shares in the companies that it refers to MarketByte LLC.  The above relationships should be viewed as a potential and/or actual conflict of interest by shareholders and prospective shareholders of MarketByte LLC client companies. 

The profiles, critiques, and other editorial content of the OTCjournal.com may contain statements that appear foward relating to the expected capabilities of the companies mentioned herein.

THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN  SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN  CONSENT OF THE EDITORS OF OTCjournal.com.

We encourage our readers to invest carefully and read the investor information available at the web sites of  the Securities and Exchange Commission ("SEC") at http://www.sec.govand/or the National Association of Securities Dealers ("NASD") at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at  http://www.sec.gov/consumer/cyberfr.htm. Disclaimer ID:$subst('Recip.userid') Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.  MarketByte LLC's mailing address is 4653 Carmel Mtn Rd Suite 308 #402, San Diego, CA 92130.